Intra-Cellular Therapies Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$20.9M
Industry:Pharma
Founded:N/A
Lead Investor(s):J.P. Morgan Securities LLC, Leerink Partners LLC
Press

Estimated Revenue & Financials

  • Intra-Cellular Therapies's estimated revenue is currently $9.2M per year.
  • Intra-Cellular Therapies received $150.0M in venture funding in September 2017.
  • Intra-Cellular Therapies's estimated revenue per employee is $162211
  • Intra-Cellular Therapies's total funding is $20.9M.

Employee Data

  • Intra-Cellular Therapies has 57 Employees.
  • Intra-Cellular Therapies grew their employee count by 24% last year.
  • Intra-Cellular Therapies currently has 1 job openings.

Executive Contacts

NameTitle
Sharon MatesFounder, Chairman & Chief Executive Officer
Lawrence HinelineSenior Vice President of Finance & Chief Financial Officer
Kimberly VanoverSenior Vice President, Early Stage Clinical Development and Translational Medicine
Juan SanchezVP Corporate Communications/Investor Relations
Susan KozauerVP Clinical Development
Derek LevandaDirector, Supply Chain
Laura LlewellynDirector, Clinical Project Management
Mark NeumannExecutive Vice President, Chief Commercial Officer
Michael HalsteadEVP/General Counsel
John TorigianDirector CMC Quality and Document Management

What Is Intra-Cellular Therapies?

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications. Use link below for a listing of Job Opportunities: https://www.linkedin.com/jobs/search/keywords=intra-cellular%20therapies&location=United%20States&locationId=us%3A0

keywords:Biotechnology,Healthcare,Pharmaceuticals

57

Number of Employees

$9.2M

Revenue (est)

1

Current Jobs

24%

Employee Growth %

$20.9M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Symbio Research
$10.9M6011%
Innovation Asso...
$33M18815%
Insight Strateg...
$6.1M5826%
CBPartners
$11.9M7019%
LI Script LLC
$10.9M552%
Medical Knowled...
$15.5M8816%
CHDI Foundation
$12.1M635%
Intra-Cellular ...
$9.2M5724%$20.9M
Lornamead
$20.7M1052%
Rochem Internat...
$8M425%

Intra-Cellular Therapies News

12-Sep-19 - Turns Out, It Wasn't Bad News for Intra-Cellular Therapies

The Food and Drug Administration told Intra-Cellular Therapies (NASDAQ:ITCI) that it doesn't plan to hold an advisory committee meeting to ...

12-Sep-19 - Intra-Cellular Therapies Provides Lumateperone Regulatory Update

Intra-Cellular Therapies is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the ...

12-Sep-19 - Intra-Cellular provides lumateperone update; shares up 6% premarket

The FDA has informed Intra-Cellular Therapies (NASDAQ:ITCI) that it has no plans to schedule an Advisory Committee meeting regarding the ...

Intra-Cellular Therapies Funding

DateAmountRoundLead InvestorsReference
2014-02-03$100.2MUndisclosedLeerink Partners LLCArticle
2014-02-06$115.3MUndisclosedLeerink Partners LLCArticle
2015-03-09$106.5MUndisclosedLeerink Partners LLCArticle
2015-03-13$121.4MUndisclosedLeerink Partners LLC,Article
2017-09-29$150.0MUndisclosedJ.P. Morgan Securities LLCArticle

Intra-Cellular Therapies Executive Hires

DateNameTitleReference
2014-03-11Juan SanchezVP Corporate Communications/Investor RelationsArticle
2018-08-21Suresh DurgamSVP Late Stage Clinical Development & Medical Affairs.Article
2018-09-26Michael OlchaskeySVP/Head of Regulatory AffairsArticle